Retatrutide – 40mg
Research-grade Retatrutide (LY-3437943), a synthetic triple GLP-1/GIP/glucagon receptor agonist peptide studied for advanced metabolic research. 40mg lyophilized powder, 99%+ purity verified by Janoshik Analytical via HPLC and mass spectrometry. CAS 2381089-83-2.
For laboratory research use only.
Not for human or veterinary use.
Not intended for diagnosis, treatment, cure, or prevention of any disease.
Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.
Retatrutide (LY-3437943) is a synthetic triple-receptor agonist peptide that Durham Peptides supplies as research-grade 10 mg lyophilized vials, stocked and shipped domestically for researchers across Canada. It acts on three metabolic pathways at once — GLP-1, GIP, and glucagon — and is sometimes informally called "GLP-3" for this three-receptor mechanism.
Because it engages an additional glucagon pathway beyond dual-agonist compounds, retatrutide is frequently studied alongside Semaglutide (a mono-agonist) and Tirzepatide (a dual-agonist) to compare multi-receptor pharmacology. Durham Peptides stocks all three for comparative research.
BENEFITS
Triple receptor activation — studied for simultaneous GLP-1, GIP, and glucagon engagement
Metabolic research — explored in Phase 2 clinical trials with notable body-composition results
Glucagon component — linked to thermogenesis and energy-expenditure pathways
Next-generation compound — investigated as an advancement over dual-agonist approaches
Comparative pharmacology — assessed alongside mono- and dual-agonists in research settings
WHAT RESEARCHERS LOOK AT
Triple-agonist binding affinity across GLP-1, GIP, and glucagon receptors
Additive effects of glucagon-receptor activation on energy expenditure
Dose-response and tolerability profiling from clinical-trial data
Comparative outcomes vs tirzepatide and semaglutide
Pharmacokinetic profiling and receptor selectivity
